| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Alkyl-Chain
PROTAC Linkers. |
|---|---|
| ln Vitro |
As a linker molecule, 7-Octynoic acid itself has no intrinsic biological activity; it serves as a structural connector to join a target protein ligand and an E3 ubiquitin ligase ligand in PROTAC synthesis. The terminal alkyne group is a click chemistry handle that can undergo CuAAc with azide-containing molecules to form a stable triazole linkage. This reaction is highly specific and can be performed under mild conditions. The carboxylic acid can be activated with EDC and NHS to form an amide bond with primary amine-containing ligands. The orthogonal functional groups (alkyne and carboxylic acid) enable stepwise conjugation to two different ligands. The C7 alkyl spacer provides a moderate-length, flexible, and hydrophobic connection between the conjugated ligands.
|
| ln Vivo |
No specific in vivo activity has been reported for this linker alone; its activity is derived from the final PROTAC molecule after conjugation with appropriate ligands. The in vivo efficacy of a complete PROTAC is determined in animal models.
|
| Enzyme Assay |
N/A; this compound is not assessed in isolated enzyme/receptor binding assays. As a synthetic intermediate, its quality is typically confirmed by analytical methods such as HPLC and NMR, with a standard purity of ≥95%. The alkyne group can be characterized by its characteristic IR absorption at around 2100-2260 cm-1. The terminal alkyne proton in 1H NMR typically appears as a triplet around 2.4-2.5 ppm (J ≈ 2.5 Hz) or a singlet around 2.0-3.0 ppm depending on the substitution pattern. The IUPAC name is oct-7-ynoic acid.
|
| Cell Assay |
N/A; this linker is not tested alone in cell-based assays. It is used as a building block for constructing PROTACs. In a typical synthesis, the alkyne group is reacted with an azide-containing ligand via CuAAc using CuSO4 and sodium ascorbate as catalyst in a THF/water mixture. The carboxylic acid is activated with EDC and NHS and reacted with a primary amine-containing ligand to form an amide bond. The resulting PROTAC is then tested in cells for target degradation activity. The C7 alkyl spacer may be optimal for certain target-E3 ligase pairs that require a moderate-length, flexible linker.
|
| Animal Protocol |
N/A; no animal studies are performed with the linker alone. For a complete PROTAC conjugate, in vivo studies are conducted following institutional guidelines. The compound is typically formulated using a vehicle containing DMSO, PEG300, Tween-80, and saline and administered via intraperitoneal (IP) or intravenous (IV) injection. The C7 alkyl spacer may affect the lipophilicity and cellular permeability of the final PROTAC.
|
| ADME/Pharmacokinetics |
This compound has a molecular weight of 140.18, a molecular formula of C8H12O2, and a standard purity of ≥95%. The IUPAC name is oct-7-ynoic acid. It appears as a liquid. For storage, it should be kept long-term in a cool, dry place, sealed, away from moisture. It is soluble in DMSO and other organic solvents. The product should be stored away from oxidizing agents. CAS: 10297-09-3.
|
| Toxicity/Toxicokinetics |
This product is for research use only and is not for human or veterinary use. Standard chemical safety precautions should be observed during handling. The alkyne group should be handled with care to avoid premature reactions. The product should be stored away from oxidizing agents. It is not an approved therapeutic drug and has not been cleared for clinical use. PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license.
|
| References | |
| Additional Infomation |
7-Octenic acid is a medium-chain fatty acid.
7-Octynoic acid is a simple, linear, heterobifunctional alkyl linker that combines a click chemistry handle (terminal alkyne) with a carboxylic acid for amide coupling. The C7 alkyl chain provides a moderate-length, flexible spacer that is hydrophobic, which can be beneficial for PROTACs targeting intracellular proteins where a certain degree of lipophilicity is required for cellular permeability. The terminal alkyne enables CuAAc click chemistry with azide-functionalized ligands, providing a versatile and efficient conjugation strategy. This linker is a valuable building block for PROTAC libraries and for bioconjugation applications. |
| Molecular Formula |
C8H12O2
|
|---|---|
| Molecular Weight |
140.18
|
| Exact Mass |
140.084
|
| CAS # |
10297-09-3
|
| PubChem CID |
5312700
|
| Appearance |
Colorless to light pink liquid
|
| LogP |
1.654
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
10
|
| Complexity |
141
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C#CCCCCCC(=O)O
|
| InChi Key |
WJBHDZBQZOMDFF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H12O2/c1-2-3-4-5-6-7-8(9)10/h1H,3-7H2,(H,9,10)
|
| Chemical Name |
oct-7-ynoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~150 mg/mL (~1070.05 mM)
H2O :~5 mg/mL (~35.67 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.75 mg/mL (26.75 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 37.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3.75 mg/mL (26.75 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 37.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3.75 mg/mL (26.75 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (713.37 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.1337 mL | 35.6684 mL | 71.3369 mL | |
| 5 mM | 1.4267 mL | 7.1337 mL | 14.2674 mL | |
| 10 mM | 0.7134 mL | 3.5668 mL | 7.1337 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
